Guided surveillance and less invasive neck surgery for advanced nasopharyngeal cancer
Part of Cancer clinical trials.
This trial tests a new way of managing advanced nasopharyngeal cancer that has spread to the neck after radiation therapy. It uses regular imaging and exams to guide a less invasive neck surgery, aiming to remove any remaining cancer while preserving healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a specific type of nasopharyngeal cancer (a cancer in the upper throat behind the nose) confirmed by biopsy.
- Your cancer has spread to lymph nodes in the neck (called N3) but not to other parts of the body.
- You are able to perform your usual daily activities with little or no help (ECOG score 0 or 1).
- You have not had surgery to remove lymph nodes in your neck before.
- Your blood counts and liver/kidney function are within acceptable levels for this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
This trial tests whether shrinking the area that gets radiation in the nasal cavity can reduce side effects while still treating the cancer effectively. If you have nasopharyngeal cancer that has spread into your nose, this study might help lower radiation exposure to that area.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.